Cognicept (donepezil/solifenacin) / AbbVie - LARVOL DELTA

Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010 - 2020. (PubMed, J Prev Alzheimers Dis) - "The molecules Elenbecestat and LY3202626 decreased the burden of Aβ plaques without significant cognitive improvement, Donanemab is in Phase 3 clinical trial, and the FDA has designated it Breakthrough Therapy. CPC-201 and PXT864 demonstrated, in Phase 2, good tolerability and improvement of AD symptoms...The most advanced treatments in their research are those focused on treating Aβ accumulation. More studies are needed to prove the efficacy of the patented molecules."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Immunology • Inflammation

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease. (PubMed) - Neurotherapeutics - "Clinical Global Impression of Improvement scores improved by 0.94 ± 0.20 to 3.1 ± 0.20 points (p < 0.001). The findings suggest that limiting donepezil AEs by co-administration of solifenacin allows the safe administration of substantially higher cholinesterase inhibitors doses that may augment cognitive and global benefits in patients with AD."

Journal • Alzheimer's Disease • Biosimilar

CPC-12: A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type (clinicaltrials.gov) - P2; N=28; Completed; Sponsor: Chase Pharmaceuticals Corporation; Active, not recruiting ➔ Completed; N=20 ➔ 28

Enrollment change • Trial completion • Alzheimer's Disease • Biosimilar • CNS Disorders • Reperfusion Injury

Allergan chases high dose, low side effects Alzheimer’s combo in biotech buy (FierceBiotech) - "In an analyst note from Bernstein...found two patents assigned to Chase: 8,404,701 and 9,044,472 (both expire March 2028)...'The ‘701 patent claims a method of raising the therapeutic effect of acetyl choline esterase inhibitors (i.e. Aricept) by adding a peripheral muscarinic anticholinergic agent (PAChA)....The ‘472 patent claims the formulation of the two drugs together.'...'We expect this drug would reach the market by ~2020.' "

Anticipated launch US • Anticipated patent expiry • Alzheimer's Disease

CPC-12: A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type (clinicaltrials.gov) - P2; N=20; Recruiting; Sponsor: Chase Pharmaceuticals Corporation; Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • Biosimilar • Reperfusion Injury